Meeting
2024 ASCO Annual Meeting
A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).
Authors
Maha H. A. Hussain
Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
Maha H. A. Hussain , Masha Kocherginsky , Parminder Singh , Winston Tan , Zin Myint , Di (Maria) Jiang , Elizabeth Marie Wulff-Burchfield , Yangruijue Ma , Elad Sharon , Richard Piekarz , Joshua J Meeks , David James VanderWeele
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03854474
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 4574)
DOI
10.1200/JCO.2024.42.16_suppl.4574
Abstract #
4574
Poster Bd #
269
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).
First Author: Maha H. A. Hussain
Poster
2020 Genitourinary Cancers Symposium
A pilot study of tazemetostat and MK-3475 (pembrolizumab) in advanced urothelial carcinoma (ETCTN 10183).
First Author: Joshua J. Meeks
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of nanosomal docetaxel lipid suspension (NDLS) in patients with advanced gastric adenocarcinoma.
First Author: Vikas S. Ostwal
Poster
2023 ASCO Annual Meeting
Tazemetostat, a selective EZH2 inhibitor, with pembrolizumab as treatment of anti-PD-1 resistant head and neck squamous-cell carcinoma (HNSCC): A phase 1-2 trial.
First Author: Sidharth Puram